Growth Hormone Deficiency (GHD)
11
3
3
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
9.1%
1 terminated out of 11 trials
80.0%
-6.6% vs benchmark
45%
5 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (11)
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
GB06 Phase III Trial for Pediatric Growth Hormone Deficiency
REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)
Hypothalamic-Stratified Nursing Pathway for Pediatric Craniopharyngioma
Development of a Personalized Growth Hormone Treatment Profile (PGTP) Report for Pediatric Endocrinology
Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency
Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study
Treatment of Children With Insufficient Secretion of Growth Hormone